Pancreatic Cancer Research

ResearcherShanghai UniversityActive in the last 2 years

Marko Kornmann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9533-8711; OpenAlex author ID A5000033879, A5015250184. Sources: OpenAlex.

Their work

Papers
32 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
2
Collaborators
79
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 4 papers · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 3 papers · 2021: 6 papers · 2022: 5 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 32

  1. Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution Co-author DOI 10.1101/2025.04.24.650216↗
  2. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  3. c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1. Last author DOI 10.1038/s41417-020-00290-5↗
  4. Editorial: Multimodality Treatment in Pancreatic Ductal Adenocarcinoma - Current Options and the Future Impact of Molecular Biological Profiling. Co-author DOI 10.1159/000521419↗
  5. Discussion: Current Multimodality Treatment Options in Pancreatic Cancer in Clinical Practice - What Is the Future Impact of Molecular Biological Profiling? Last author DOI 10.1159/000521847↗
  6. JNK inhibitor IX restrains pancreatic cancer through p53 and p21. Co-author DOI 10.3389/fonc.2022.1006131↗
  7. Loss of Interleukin-13-Receptor-Alpha-1 Induces Apoptosis and Promotes EMT in Pancreatic Cancer. Co-author DOI 10.3390/ijms23073659↗
  8. Curing pancreatic cancer. Last author DOI 10.1016/j.semcancer.2021.05.030↗
  9. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death. Co-author DOI 10.21873/anticanres.15416↗
  10. The Role of Exosomes in Pancreatic Cancer From Bench to Clinical Application: An Updated Review. Co-author DOI 10.3389/fonc.2021.644358↗
  11. A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Co-author DOI 10.3390/cancers13112539↗
  12. Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer. Last author DOI 10.3390/ijms22062998↗
  13. Stress-activated kinases as therapeutic targets in pancreatic cancer. Co-author DOI 10.3748/wjg.v27.i30.4963↗
  14. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway. Co-author DOI 10.1016/j.canlet.2020.06.009↗
  15. Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning. Co-author DOI 10.1158/1078-0432.ccr-19-1247↗
  16. Opposing Oncogenic Functions of p38 Mitogen-activated Protein Kinase Alpha and Beta in Human Pancreatic Cancer Cells. Last author DOI 10.21873/anticanres.14567↗
  17. BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2019.02.031↗
  18. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  19. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  20. Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer. Co-author DOI 10.3892/or.2018.6178↗
  21. Long noncoding RNA H19 derived miR-675 regulates cell proliferation by down-regulating E2F-1 in human pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/jca.21347↗
  22. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling. Co-author DOI 10.1016/j.canlet.2017.05.006↗
  23. Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo. Last author DOI 10.3390/ijms18040716↗
  24. The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384047.2016.1219814↗
  25. Hedgehog Signaling Regulates Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem-Like Cells. Co-author DOI 10.7150/jca.13305↗
  26. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Co-author DOI 10.1016/j.ejca.2014.05.017↗
  27. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Co-author DOI 10.1093/annonc/mdt270↗
  28. Inhibition of pancreatic cancer cell growth in vivo using a tetracycline-inducible cyclin D1 antisense expression system. Last author DOI 10.1097/mpa.0b013e3182546de5↗
  29. Absence of FLICE-inhibitory protein is a novel independent prognostic marker for very short survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31829655ed↗
  30. Brain metastasis in pancreatic cancer. Last author DOI 10.3390/ijms14024163↗
  31. Interactions of pancreatic cancer and stellate cells are mediated by FGFR1-III isoform expression. Last author DOI 10.5754/hge10366↗
  32. Long-term survival following resection of brain metastases from pancreatic cancer. Last author PMID 22199336↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Benno Traub · 9 shared papers, 2017–2022 · strength 1.42
  2. Alexander Kleger · 7 shared papers, 2013–2025 · strength 1.02
  3. Jingwei Shi · 4 shared papers, 2021–2022 · strength 0.67
  4. Yinmo Yang · 7 shared papers, 2016–2020 · strength 0.55
  5. Thomas Jens Ettrich · 5 shared papers, 2018–2025 · strength 0.54
  6. Thomas Theodor Werner Seufferlein · 5 shared papers, 2018–2025 · strength 0.54
  7. Lukas Perkhofer · 4 shared papers, 2018–2025 · strength 0.47
  8. Huahu Guo · 5 shared papers, 2017–2020 · strength 0.43
  9. Feng Wang · 6 shared papers, 2016–2019 · strength 0.43
  10. Ling Ma · 6 shared papers, 2016–2019 · strength 0.43
  11. Zhengkui Zhang · 6 shared papers, 2016–2019 · strength 0.43
  12. Xiaodong Tian · 5 shared papers, 2016–2020 · strength 0.42
  13. Johannes Lemke · 5 shared papers, 2011–2021 · strength 0.41
  14. Yinmo Yang · 3 shared papers, 2014–2022 · strength 0.40
  15. Chong Du · 5 shared papers, 2016–2019 · strength 0.37
  16. Helmut Friess · 3 shared papers, 2019–2023 · strength 0.37
  17. Alica K. Beutel · 3 shared papers, 2019–2025 · strength 0.36
  18. Xiaodong Tian · 4 shared papers, 2014–2021 · strength 0.36
  19. Xiaodong Tian · 3 shared papers, 2012–2022 · strength 0.31
  20. Kai Chen · 2 shared papers, 2020–2021 · strength 0.30
  21. Hans Armin Kestler · 2 shared papers, 2021–2025 · strength 0.29
  22. Élodie Roger · 2 shared papers, 2021–2025 · strength 0.29
  23. Johann Gout · 2 shared papers, 2021–2025 · strength 0.29
  24. Eike Gallmeier · 3 shared papers, 2018–2023 · strength 0.25
  25. Andrea Tannapfel · 3 shared papers, 2018–2023 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.